{
    "clinical_study": {
        "@rank": "88926", 
        "acronym": "FLUVAC EV-02", 
        "arm_group": {
            "arm_group_label": "Nasopharyngeal sample", 
            "arm_group_type": "Experimental", 
            "description": "one will be taken nasopharyngeal all patients hospitalized for 24 hours with ILI in the last seven days."
        }, 
        "brief_summary": {
            "textblock": "This study assesses the seasonal of influenza vaccine effectiveness in adults hospitalised\n      with laboratory-confirmed influenza through a network of hospitals in France"
        }, 
        "brief_title": "Clinical Trial to Assess the Influenza Vaccination (FLUVAC 02)", 
        "completion_date": {
            "#text": "May 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Adult Hospitalized", 
        "condition_browse": {
            "mesh_term": "Influenza, Human"
        }, 
        "detailed_description": {
            "textblock": "Influenza vaccination strategies aim at protecting high-risk population from severe\n      outcomes. Estimating the effectiveness of seasonal vaccines against influenza related\n      hospitalisation is important to guide these strategies. The objective is to measure the\n      population effectiveness of influenza vaccine in patients hospitalized with virologically\n      confirmed influenza laboratory during the influenza season 2012/2013 in a French hospitals\n      network. This is a study \"case-control\" involving a nasopharyngeal sample for all\n      hospitalised patients presenting an influenza-like illness within seven days. Cases will be\n      patients RT-PCR positive for influenza. Controls will be patients negative for any influenza\n      virus."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age \u2265 18 year\n\n          -  Affiliated with social security health insurance\n\n          -  Written informed consent\n\n          -  Patients hospitalized for 24 hours and presenting an influenza-like illness in the\n             last 7 days before the hospitalization\n\n        Exclusion Criteria:\n\n          -  Against indication for influenza vaccination(Hypersensitivity to the active\n             substances, to any of the excipients and to trace eg eggs, including ovalbumin,\n             chicken protein)\n\n          -  Patients institutionalized without regular community interaction\n\n          -  Patient already hospitalized for respiratory infection during the 2012-2013\n             influenza season\n\n          -  Flu already virologically documented in the current influenza season 2012-2013\n             (RT-PCR, multiple RT-PCR and / or culture.)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 21, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01764152", 
            "org_study_id": "C12-57", 
            "secondary_id": "2012-A01118-35"
        }, 
        "intervention": {
            "arm_group_label": "Nasopharyngeal sample", 
            "description": "The nasopharyngeal sample will be used to find the types and subtypes of influenza virus and other respiratory viruses.", 
            "intervention_name": "nasopharyngeal sample", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Prevention,", 
            "influenza,", 
            "adults hospitalized,", 
            "vaccines,", 
            "Effectiveness"
        ], 
        "lastchanged_date": "January 7, 2013", 
        "location": {
            "contact": {
                "email": "odile.launay@cch.aphp.fr", 
                "last_name": "Odile Launay, PU-PH", 
                "phone": "+33(0)1 58 41 18 60"
            }, 
            "contact_backup": {
                "email": "carrat@u707.jussieu.fr", 
                "last_name": "Fabrice Carrat, Pu-PH", 
                "phone": "+33(0)1 44 73 84 58"
            }, 
            "facility": {
                "address": {
                    "city": "Paris", 
                    "country": "France", 
                    "zip": "75654"
                }, 
                "name": "Institut National de la Sant\u00e9 Et de la Recherche M\u00e9dicale"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "Efficiency in Population of Influenza Vaccination for Seasonal 2012-2013 for Flu Prevention of the Hospitalized Adults: an Observational Study", 
        "overall_contact": {
            "email": "odile.launay@cch.aphp.fr", 
            "last_name": "Odile Launay, PU-PH", 
            "phone": "+33(0)1 58 41 18 60"
        }, 
        "overall_contact_backup": {
            "email": "carrat@u707.jussieu.fr", 
            "last_name": "Fabrice Carrat, PU-PH", 
            "phone": "+33(0)1 44 73 84 58"
        }, 
        "overall_official": {
            "affiliation": "Assistance Publique - H\u00f4pitaux de Paris", 
            "last_name": "Odile Launay, PU-PH", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The effectiveness of the vaccine in population will be calculated according to the formula VE = 1 - OR. an interval exact confidence of 95% will be calculated on the point estimate.", 
            "measure": "Measure of vaccine efficacy in population by comparing the number of influenza cases virologically documented in hospitalized patients vaccinated and unvaccinated.", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01764152"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Measure of vaccine efficacy in population by comparing the number of influenza cases virologically documented in hospitalized patients vaccinated and unvaccinated according to age groups", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Measure of vaccine efficacy in population by comparing the number of influenza cases virologically documented in hospitalized patients vaccinated and unvaccinated depending on the subtypes.", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Description of the population hospitalized for ILI (socio-demographic characteristics, risk factors, pattern and duration of hospitalization...)", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "source": "Institut National de la Sant\u00e9 Et de la Recherche M\u00e9dicale, France", 
        "sponsors": {
            "collaborator": {
                "agency": "Sanofi", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Institut National de la Sant\u00e9 Et de la Recherche M\u00e9dicale, France", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}